While immune checkpoint inhibitors are generally considered more effective than TKIs in renal cell carcinomas with sarcomatoid or rhabdoid features, our findings raise the possibility that TKI-based therapy may retain therapeutic relevance in select cases, particularly in Cluster C tumors characterized by PI3K/mTOR pathway activation. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.